Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 222 participants.

Also called NCT02640794

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 222 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02640794
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada, Chile, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02640794. Randomized; no masking; primary purpose prevention. Start 2015-01 (actual); primary completion 2017-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI
Acronym
ARTE
Condition
Aortic Valve Disease
Condition
Stroke
Condition
Bleeding
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Aspirin
Lead sponsor
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec (class: other)

Record details

Record id
cardio:ct-nct02640794
Content hash
0b666d1c629e84493c80175d497f6f723b74111b35162ae28381c3dc1e422883